Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Patent
1990-01-22
1994-05-24
Draper, Garnette D.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
5303871, 5303873, 5303877, 5303883, 5303884, 5303885, 5303886, 5303888, 53038885, 5303917, 5303919, 435 695, 435 6952, 435 697, 435 702, 435 7021, 424 858, 424 851, 424 852, 424 8591, 935 47, C07K 1300
Patent
active
053149955
ABSTRACT:
The present invention relates to antibody-based fusion proteins wherein a portion of an immunoglobulin molecule is linked to a biologically active ligand. In particular embodiments of the invention, the fusion protein comprises a portion of an antibody which recognizes a cell surface antigen linked to a ligand which is a lymphokine or a cellular factor. A preferred embodiment of the fusion protein comprises the variable region of the anti-tumor monoclonal antibody L6 and an active lymphokine molecule such as IL-2. In another preferred embodiment of the present invention, the fusion protein comprises the variable region of the L6 monoclonal antibody and active platelet factor 4. The antibody-based fusion proteins of the invention may be used therapeutically to deliver biologically active ligands to a specific target cell or tissue.
REFERENCES:
patent: 4935352 (1990-06-01), Koichi et al.
patent: 5095096 (1992-03-01), Miki et al.
Ikeyama, Mol. Immunol., vol 24(10), 1987, pp. 1039-1046.
Chaudhary et al., 1989, Nature, 339:394-397.
Hellstrom et al., 1984, in Monoclonal Antibodies and Cancer, Wright et al. (eds.), Marcel Dekker, Inc., N.Y., pp. 31-47 ("Hellstrom I").
Hellstrom et al., 1985, in Monoclonal Antibodies for Cancer Detection and Therapy, Baldwin et al. (eds.), Academic Press, N.Y., pp. 17-51 ("Hellstrom II").
Kelley et al., 1988, Proc. Natl. Acad. Sci. USA, 85:3980-3984.
Kirkman et al., 1989, Transplantation, 47, (No. 2):327-330.
Kiyokawa et al., 1989, Cancer Res., 49:4042-4046.
Morrison et al., 1984, Proc. Natl. Acad. Sci. USA, 81:6851-6855 ("Morrison I").
Morrison, 1985, Science, 229:1202-1207 ("Morrison II").
Murphy, 1988, in Immunotoxins, Frankel (ed.), Kluwer Academic Publishers, pp. 123-140.
Neuberger et al., 1984, Nature, 312:604-608.
Roberge et al., 1989, J. Immunol., 143, (No. 11): 3498-3502.
Sahagan et al., J. Immunol., 137, (No. 3): 1066-1074.
Sun et al., 1987, Proc. Natl. Acad. Sci. USA, 84:214-218.
Walz et al., Jan. 1990, Transplantation, 49, (No. 1): 198-201.
Williams et al., 1986, Gene, 43:319-324.
Sasada et al., Cell Structure and Function, 13, 1988, pp. 129-141.
Senoo et al., CA, vol. 104, 1986, #220129c.
Gross et al., PNAS 86, 1989, pp. 10024-10028.
Ashenozi et al., CA, vol. 116(3), 1991, #19532h.
Morrison et al., CA, 116(3), 1991, #19660a.
Schnee et al., PNAS, vol. 84, No. 1987, pp. 6904-6908.
Traunecker et al., Nature, 339, 1989, pp. 68-70.
Fell, Jr. Henry P.
Gayle Margit A.
Draper Garnette D.
Oncogen
LandOfFree
Therapeutic interleukin-2-antibody based fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic interleukin-2-antibody based fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic interleukin-2-antibody based fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1973667